Teriparatide biosimilar (Shanghai Duomirui)

特立帕肽生物类似药 (上海多米瑞)

Report date: 2024/10/10 11:44:04

Base Information

Drug NameTeriparatide biosimilar (Shanghai Duomirui)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionParathyroid hormone replacementsParathyroid hormone receptor agonists
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Duomirui Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Duomirui Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A